HPBCD treatment improves learning and executive function in Alzheimer model mice

Posted by

Earlier we have reported on a patent appication related to HPBCD treatment in Alzheimer’s disease based on the invention of Dr. Tsai’s group at MIT:

Now, the research has been reported also by journal Nature on 16 November 2022, (Blanchard, J.W., Akay, L.A., Davila-Velderrain, J. et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature (2022)., which is at the time being open access, through this link:

The main conclusion of the research:

The team treated some APOE4-expressing mice (APOE4 is the strongest risk factor gene for Alzheimer’s disease) with cyclodextrin, left others untreated, and subjected them all to two different memory tests.  The cyclodextrin-treated mice performed both tests significantly better, suggesting an association between improved myelination and improved cognition.

Based on these research data a clear picture is emerging in which intervening to correct specific lipid dysregulations by cell type could potentially help counteract APOE4’s contributions to Alzheimer’s pathology.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.